Navigation Links
Shire Targets Fourth Quarter Filing of BLA for REPLAGAL(R) for Fabry Disease With U.S. FDA
Date:10/21/2009

CAMBRIDGE, Massachusetts, October 21 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces plans to file a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for REPLAGAL(R) (agalsidase alfa), its enzyme replacement therapy for Fabry disease, by the end of the year. The Company also announces that a treatment protocol for REPLAGAL, filed at the request of FDA, has been approved, and that it will support emergency IND requests. The early access program is being put in place in view of the announced supply restriction of the only currently marketed treatment for Fabry disease in the United States.

"We are eager to have the opportunity to offer REPLAGAL to Fabry patients in the United States," commented Sylvie Gregoire, President of Shire Human Genetic Therapies. "There is an abundance of long-term experience with REPLAGAL in Fabry patients since the product has been commercially available outside of the United States since 2001."

The treatment protocol and emergency IND will allow physicians to treat Fabry patients with REPLAGAL in advance of potential commercial availability in the U.S. Shire will initially provide REPLAGAL free of charge to patients. The current supply of REPLAGAL is projected to be adequate to meet anticipated global demand.

Patients and physicians can contact Shire's OnePath SM for more information: +1-866-888-0660, or http://www.onepath.com.

About REPLAGAL(R) (agalsidase alfa)

REPLAGAL is a human form of enzyme alpha-galactosidase A (a-Gal A) manufactured in a human cell line by gene activation. REPLAGAL is approved in 45 countries worldwide. REPLAGAL is not currently approved for commercial sale in the U.S.'/>"/>

SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
2. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
3. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
4. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
5. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
6. Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
7. Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
8. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
9. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
10. Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
11. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Manufacturers, suppliers and distributors of ... able to protect their most important business ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because ... Device Industry, it steadfastly remains one of ... involving IP infringement. This litigious nature can ...
(Date:1/15/2014)... 2014 Tegra Medical is very pleased to ... as its new Chief Executive Officer.  Mark was ... in which he has overseen the company,s four facilities ... , and Costa Rica.  Mr. King joined Tegra ... sales, engineering and manufacturing experience in medical device businesses, ...
(Date:1/15/2014)... , Jan. 15, 2014  Echo Therapeutics, ... medical device company developing its Symphony® CGM System ... today announced that Robert F. Doman , ... will present at "TEN", Noble Financial Capital Markets, ... Doman will make a corporate presentation to prospective ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... S.r.l. a full service and,leading clinical research organization (CRO), ... Research S.r.l., a CRO focused on Phase I to,Phase ... http://www.newscom.com/cgi-bin/prnh/20080122/335477 ) , ... and have legal and,operating offices in Milan, Italy. The ...
... DIO Rats Highlighted -PLYMOUTH MEETING, Pa., Jan. 22 ... GENR ) today announced a poster presentation ... drug candidate for the treatment of type 2 ... - Novel Aspects of the Regulation of Body ...
Cached Medicine Technology:Phidea Srl and Marvin Research Srl Announce Completion of Merger 2Phidea Srl and Marvin Research Srl Announce Completion of Merger 3Genaera Presents Promising Preclinical Data for Trodusquemine (MSI-1436) at Keystone Symposia 2Genaera Presents Promising Preclinical Data for Trodusquemine (MSI-1436) at Keystone Symposia 3
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... and Soothes Young Throats Now Available,Across the Northern ... cough and cold season,rapidly approaches, Integrated Beverage Group, ... products has launched its newest product,in Canada -- ... a perfect choice for parents who wish to,choose ...
... Company to Serve About 50,000 People Beginning February 1, ... AMERIGROUP,Corporation (NYSE: AGP ) announced today that the ... authorizing the Company,s Nevada subsidiary to,enter that State,s Medicaid ... 2009., The Nevada State Board of Examiners has ...
... lead to new treatments, researchers say , , WEDNESDAY, Nov. ... cells exhausted from fighting HIV infection has been discovered ... a molecule called Tim-3 is present at high levels ... HIV, the virus that causes AIDS. Blocking the activity ...
... Expertise to ... ... the,election of Jay Parsons to the company,s board of directors effective,immediately., ... programs and the development of customized incentive programs,that help consumers make ...
... likely to skip medicines, compared to whites , , WEDNESDAY, ... that included encouragement and occasional gifts improved medication adherence ... Americans with high blood pressure, a new study found. ... be nearly twice as likely to not take their ...
... That Demonstrate Best Strategic Use of Mergers ... ... Deal,( http://www.thedeal.com ) magazine has named Abbott,( http://www.abbott.com )as the healthcare ... honored Abbott for the,most effective strategic use of acquisitions and divestitures., ...
Cached Medicine News:Health News:Integrated Beverage Group Launches Children's Throat Cooler(R) in Canada 2Health News:Integrated Beverage Group Launches Children's Throat Cooler(R) in Canada 3Health News:Nevada Gives Final Approval to AMERIGROUP Medicaid Contract 2Health News:Nevada Gives Final Approval to AMERIGROUP Medicaid Contract 3Health News:Nevada Gives Final Approval to AMERIGROUP Medicaid Contract 4Health News:Way to Rescue Tired Immune Cells Fighting HIV Found 2Health News:MedVantx(R) Names Newest Board Member 2Health News:Education Program Spurs Blacks to Take Blood Pressure Meds 2Health News:Abbott Honored as One of The Deal's Most Admired Corporate Dealmakers 2Health News:Abbott Honored as One of The Deal's Most Admired Corporate Dealmakers 3
60 month warranty; Internal Calibration Mass System Diagnostic to alert operator of abnormal weighing conditions; built-in motorized calibration weight enabling automatic self calibration....
Can download data from your A&D balance directly to your PC saving time and reducing the chances of manually recording the wrong weighing data; 60 month warranty; automatic adjustable environment set...
... automated genetic analysis system. This system automatically ... linear polyacrylamide (LPA) gel, denatures and loads ... analyzes the data. Software tools let you ... automated data assessment. All to ensure unprecedented ...
ELISA kit for the quantitative determination of autoantibodies to thyroid peroxidase (TPO) in serum...
Medicine Products: